Document:

Contract Manufacturing Services Agreement

 Exhibit 10.58 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 
 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2.

 [*****] INDICATES OMITTED MATERIAL THAT IS THE 
 SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST 
 FILED SEPARATELY WITH THE COMMISSION. 

THE OMITTED MATERIAL HAS BEEN FILED 
 SEPARATELY
WITH THE COMMISSION. 
 CONTRACT MANUFACTURING SERVICES AGREEMENT 

1 PURPOSE: Procter & Gamble Pharmaceuticals, SARL. (“P&G”) and OSG Norwich Pharmaceuticals, Inc. (“OSGP”)
have entered into an Agreement, to provide and P&G will purchase Contract Manufacturing Services to produce various Products, as these terms are defined herein. This document, the “Agreement”, sets forth the obligations of the parties
and is effective upon both parties signature. 
 2 P&G AND OSGP: 
 Procter & Gamble Pharmaceuticals, SARL, with principal offices at 47, Route de Saint-Gorges 1213 Petit-Lancy 1, Switzerland hereinafter called P&G. 

OSG Norwich Pharmaceuticals, Incorporated with principal offices at 6828 State Highway 12, Norwich, New York hereinafter called OSGP. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 1 of 19

 TABLE OF CONTENTS 

 

							
	1	  	Purpose	  	 	1	  
	2	  	P&G and OSGP	  	 	1	  
		
	Table of Contents	  			
	3	  	Certain Definitions	  	 	3	  
	4	  	Contract Manufacturing Services	  	 	5	  
	5	  	Forecasts and Ordering	  	 	6	  
	6	  	Quality Control and Testing	  	 	7	  
	7	  	Supply of Materials & Products	  	 	9	  
	8	  	Change Management	  	 	9	  
	9	  	Failure To Perform	  	 	10	  
	10	  	Initiatives and Projects	  	 	11	  
	11	  	Term	  	 	11	  
	12	  	Price	  	 	11	  
	13	  	Delivery	  	 	13	  
	14	  	Payment Terms	  	 	13	  
	15	  	Invoicing	  	 	13	  
	16	  	Compliance With Laws and Safety Measures	  	 	13	  
	17	  	Acceptance and Return	  	 	14	  
	18	  	Access For P&G’s Representatives	  	 	14	  
	19	  	Security Precautions	  	 	14	  
	20	  	Confidentiality	  	 	14	  
	21	  	Intellectual Property	  	 	14	  
	22	  	OSGP’s Indemnification Of P&G	  	 	15	  
	23	  	Change in OSGP’s Ownership	  	 	15	  
	24	  	Termination For Cause	  	 	15	  
	25	  	Continuation of Supply	  	 	16	  
	26	  	Assignment	  	 	16	  
	27	  	Contractor Status	  	 	16	  
	28	  	Reporting Requirements	  	 	16	  
	29	  	Force Majeure	  	 	16	  
	30	  	Governing Law and Language	  	 	17	  
	31	  	Headings and References	  	 	17	  
	32	  	Agreement Precedence	  	 	17	  
	33	  	Mutual Support	  	 	17	  
	34	  	Notices	  	 	18	  

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 2 of 19

 3 CERTAIN DEFINITIONS: 
 3.1 “Affiliate” means any corporation, firm, partnership or other entity, which, at the time in question, is directly or indirectly owned by or controlled by, or under common control
with, P&G or OSGP, as the case may be. For the purposes of this definition, “control” shall mean the ownership, directly or indirectly, of 50% or more of the voting stock or stockholders’ equity of a corporation or, in the case of
a non-corporate entity, the right to receive 50% or more of either the profits or the assets upon dissolution. 
 3.2 “Calendar
Year” shall mean any twelve (12) month period commencing on January 1. 
 3.3 “cGMP” means current Good
Manufacturing Practices as promulgated by the U.S. FDA and as detailed in Title 21, United States Code of Federal Regulations, or when appropriate, any corresponding statutes and/or regulations of any other country’s prescription
pharmaceuticals regulating health authority / agency in the Territory, as the same may be amended or re-enacted from time to time. cGMP documentation for use in the manufacture and marketing of Product will be developed and maintained by the parties
in accordance with the cGMP Guidelines. For new Product or new SKU initiatives cGMP includes reaching an acceptable readiness state in the Norwich Plant and the specific applicable production operation(s) versus GMP regulations in time for a
successful pre-approval Inspection audit by the FDA and/or other appropriate health authority in the Territory. 
 3.4 “Confidential
Information” means all trade secrets, know how, proprietary information, techniques, or technology, and data disclosed by one party to the other party pursuant to this Agreement or generated pursuant to this Agreement, except any portion
thereof which: 
 (i) the recipient can demonstrate by its written records was known by the recipient prior to
the disclosure thereof by the disclosing party; 
 (ii) is disclosed to the recipient without restriction, after
disclosure thereof by the disclosing party, by a Third Party who has the right to make such disclosure; 
 (iii)
is or becomes part of the public domain through no breach of this Agreement by the recipient; or 
 (iv) is
independently developed by employees of the recipient without use of any of the other party’s Confidential Information. 
 3.5
“Contract Manufacturing Services” means all operations (including but not limited to Materials testing and release, receiving, making, picking, packaging, quality control, testing, storage, documentation, and/or shipment) required to
produce and distribute the Products. 
 3.6 “Date of Manufacture” means with respect to any Product, the date of first contact
of the active substance(s) in such Products with other Materials used in the manufacture of such Products. 
 3.7 “Effective
Date” means the date of execution of this Agreement. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 3 of 19

 3.8 “FDA” means the United States Food and Drug Administration and, when appropriate, any
corresponding regulatory agency in any other country in the Territory. 
 3.9 “Materials” shall mean any raw, work-in-process,
or packing materials or any finished product needed to produce Product that meets the Specifications or needed to perform necessary Contract Manufacturing Services. 
 3.10 “Norwich Plant” shall mean the North Norwich Pharmaceuticals Plant located on Route 12 in North Norwich, New York. 
 3.11 “NDA” shall mean a New Drug Application filed pursuant to the requirements of the FDA as more fully defined in 21 C.F.R. 314 as well as equivalent submissions to the appropriate
health authorities in other countries in the Territory. 
 3.12 “Product(s)” means Calcium Tablets, specification 15121219 and
any other products agreed to in writing by the parties. 
 3.13 “SLEA” means a Service Level Execution Agreement as described
in Article 5.4. 
 3.14 “Specification(s)” or “Release Specification(s)” means the written methods, formulae,
standards, making and packing standards, procedures, tests and/or test protocols for Products provided by P&G to OSGP, which shall at all times conform with the health registrations, as applicable. 

3.15 “Territory” shall mean an area that consists of a country or countries within which Contract Manufacturing Services, Product
regulatory registration, and / or Product distribution or sale are occurring or will occur. 
 3.16 “Third Party” shall mean
any person, corporation or unincorporated body other than OSGP and P&G and/or their Affiliates. 
 3.17 “Unit” means a
Stock Keeping Unit (SKU), Kg or other agreed-upon measure of Products for a specified country in the Territory. 
 3.18 “Within OSGP
Control” means OSGP shall be deemed to have control over (i) the timing of notifications by OSGP, but only to the extent that no other person except Affiliates of OSGP controls the information necessary for OSGP to give such notice,
and (ii) matters relating to its employees, property, equipment, and conduct of its business, except to the extent that Section 30, Force Majeure, applies to or affects any of the foregoing. OSGP shall not be deemed to have control over
any other factors, including but not limited to: all matters described in Section 30 of this Agreement; the inability of any supplier except Affiliates of OSGP to deliver Materials as required; the failure of any common carrier to deliver
finished goods to P&G and/or P&G’s customers, except to the extent that such failure results solely from untimely notice given or delivery made by OSGP; and the failure of P&G to perform any obligation, whether or not under this
Agreement, which directly or indirectly impacts OSGP’s obligations under this Agreement. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 4 of 19

 4. CONTRACT MANUFACTURING SERVICES: 
 4.1 Manufacturing Obligation: Pursuant to the terms and conditions of this Agreement, OSGP shall manufacture, package, distribute, and ship to P&G, and P&G shall purchase and receive
from OSGP, packaged finished goods, sample packs, semi-finished goods, and Materials of the Products. OSGP is responsible for Contract Manufacturing Services in the production and distribution of such Products. OSGP’s obligation to supply
Contract Manufacturing Services shall include the obligation to use necessary efforts (including, but not limited to, working extra hours, shifts, or days) to supply, in any three (3) month period, Products ordered by P&G up to [*****] of
volume on a Unit basis of P&G’s most recent forecast submitted for such three (3) month period pursuant to Article 5.2, unless mutually agreed to plans documented in SLEA’s for a specific Product(s) or Unit(s) dictate a higher
percentage number is appropriate for these Product(s) or Unit(s). All costs for such necessary effort will be at OSGP’s expense. OSGP shall use its reasonable commercial efforts to satisfy orders for Product quantities in any three
(3) month period in excess of [*****] of volume on a Unit basis of P&G’s most recent forecast submitted for such three (3) month period pursuant to Article 5.2, unless mutually agreed to plans documented in SLEA’s for a
specific Product(s) or Unit(s) dictate a higher or lower percentage number is appropriate for these Product(s) or Unit(s). 
 4.2
Manufacturing Standards And Warranties: 
 (a) OSGP hereby represents and warrants to P&G that the Products
shall, at the time of delivery to P&G for release consideration, have been manufactured to meet Release Specifications in accordance with cGMP’s applicable to the Products and prevailing in the applicable Territory at the time of shipment
for medicinal products for human use in the Territory, and shall not be adulterated or misbranded within the meaning of the Specifications and cGMP’s, which include the prevention of cross contamination by such classes of products or materials
as biologics (which contain live organisms), cytotoxins, and other highly active or sensitizing materials; and shall be of merchantable quality suitable for P&G’s use; provided, however, that OSGP shall not be liable for misbranding with
respect to any Product labeling or package insert text provided or used by P&G if such Product meets the Specifications. In the event of a dispute between the parties as to whether Product meets the Release Specifications or the Specifications,
final determination that a Product does or does not meet the Release Specifications or the Specifications shall be made only in accordance with the dispute resolution procedure set forth in Article 6.5 of this Agreement. 

(b) OSGP warranties shall not extend to, and hereby specifically exclude, any alteration, misbranding or failure to meet Specifications
resulting from any work done, or activities undertaken, by P&G or its subcontractors, distributors, wholesalers and others receiving the Product directly or indirectly from P&G after shipment by OSGP of Product. 

(c) OSGP has been provided by P&G with all necessary processes, trade secrets, manufacturing know-how, and trademark rights to
manufacture the Products (herein collectively referred to as “Intellectual Property”) for use in the Territory in accordance with this Agreement, and the Norwich Plant, the facilities and equipment used by OSGP to manufacture the Products
are licensed and/or qualified under cGMP’s, are in good condition. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 5 of 19

 4.3 Exclusivity: OSGP’s right and obligation in Article 4 to manufacture Products shall
be exclusively for P&G unless otherwise mutually agreed upon in writing by the parties. P&G hereby covenants that during the term of this Agreement it shall not institute any action or suit at law or equity against OSGP alleging the
infringement of any of P&G’s Intellectual Property by OSGP in its making of Product for P&G. Any improvements made by OSGP to P&G registered Products or processes whether or not patentable shall be owned by P&G. Intellectual
property from other OSGP initiated improvements shall be owned by OSGP. 
 4.4 Labeling and Packaging of Products: It is intended
that for existing Products P&G’s artwork will be consistent with OSGPs manufacturing equipment. P&G shall, at its own cost and expense, supply OSGP with the mechanical design of artwork for all Printed Matter except shipper case labels.
A technical standards document will be used to state the requirements for shipper case labels. The mechanical design for shipper case labels will be the responsibility of OSGP. P&G artwork for labeling will be subject to OSGP approval solely for
a determination of manufacturing feasibility. As used herein, “Printed Matter” means all printed materials, including labeling and leaflets, required to be affixed to and/or packaged with or accompanying Products distributed for or
delivered to P&G. Each set of such artwork, and each partial set and/or alteration or amendment thereto, for each piece of Printed Matter shall be identified by a unique item control number or code which is consistent with P&G’s control
numbering system and quality control requirements. P&G shall specify the Code for each item of Printed Matter to be supplied with each order for Products. Such Code shall be specified on the purchase order for such Products. 

4.5 Maintenance of Equipment: All equipment and tooling required to manufacture P&G’s Products will be maintained in good
operating condition by OSGP. OSGP agrees to assume complete responsibility for all maintenance. This includes (but not limited to) preventive and predictive maintenance; and replacement of worn or broken parts and tooling for all equipment and
facilities, including major components, utilized in the contract manufacturing of P&G’s Product. OSGP further agrees to maintain adequate insurance coverage and to replace said equipment should equipment for any reason be destroyed by fire,
vandalism or perils otherwise covered by an extended coverage endorsement or otherwise rendered unusable for the purpose intended by this Agreement. 
 5. FORECASTS AND ORDERING: 
 5.1 Firm Orders: P&G shall give OSGP
a firm order of its requirements of the Products at least ninety (90) days before it requires shipment of such Products. Such orders shall be in minimum order quantities, as set forth in Schedule B. OSGP shall use necessary efforts to fulfill
orders properly made hereunder by completing Contract Manufacturing Services of the Products on or prior to the date specified on the order as received. A process for handling firm order changes shall be developed and agreed between the parties
promptly after execution of this Agreement and documented in SLEA’s. 
 5.2 Forecasting: Within thirty (30) days of
completion of this Agreement and then, at least one (1) month prior to the start of each calendar quarter during the Term, P&G shall 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 6 of 19

 
give to OSGP a forecast of P&G’s estimated requirements of Products starting with the start of such quarter (or the start of the Term). Each such forecast shall be broken down by SKU by
month in respect of the first three quarters and by SKU by quarter in respect of the remaining period. 
 5.3 Customer
Service: OSGP shall maintain systems, staffing, and procedures in place to consistently maintain “excellent” customer service for P&G customers, as defined herein. “Excellent” customer service shall be measured
by the following P&G defined measures: Shipped On Time, Orders Shipped Complete, Product Availability, Same Day / Next Day Shipments, and Supplier Delivery Performance. 
 Levels for “excellence” customer service are: 
 Shipped On Time > 98%

 Shipped Complete > 98.5% 
 Product Availability = 100% 
 Same Day Shipments > 95% & 100% Within 48
Hours 
 Supplier Delivery Performance > 95% 
 OSGP will track their actual monthly performance versus the above targets (the “Monthly Targets”) and report these results to P&G monthly. If any one Monthly Target is not met and the cause
/ correction of this below target performance is Within OSGP Control, then within two weeks OSGP will develop a plan, (the “Action Plan”), agreed to by P&G which in P&G’s reasonable assessment is feasible to improve
performance to meet or exceed target. All costs associated with any such Action Plan will be the responsibility of OSGB. P&G has the right to audit OSGP’s books and records for the purpose of determining accuracy of customer service results
reported. 
 OSGP shall be construed to have failed to perform, as described in Article 11, its customer service obligations to P&G if any
of the following events occur: 
 (a.) OSGP fails to meet one particular Monthly Target for three (3) consecutive months.

 (b.) OSGP’s actual performance in any two (2) consecutive months falls below two-thirds ( 2/3) of a Monthly Target. 

5.4 Service Level Execution Agreement (SLEA) between the Parties: As soon as practicable after execution of this Agreement, the
parties shall develop Service Level Execution Agreement(s) (SLEA’s) covering the details of production planning, customer service, quality assurance, cGMP, problem solving procedures, and similar activities as between the Norwich Plant and each
P&G site; and between the Norwich Plant and the P&G European pharmaceuticals business. 
 6 QUALITY CONTROL AND TESTING:

 6.1 Testing and Certificate of Analysis: Before releasing any batch of the Materials, OSGP shall test for the compliance of
such batch with all Registered tests for their site and cGMP’s. OSGP’s Quality Assurance department at the Norwich Plant shall oversee and assure the testing is completed by the OSGP Quality Control laboratory at the Norwich Plant. Copies
of raw material, manufacturing, and inspection records will be made available for review by P&G representatives. Copies of manufacturing records and 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 7 of 19

 
certificates of analysis incorporating such certification, in the form attached hereto as Schedule E, shall be provided to P&G with each shipment of Product(s) for each batch and/or partial
batch contained in the shipment. All such copies shall be sent to the addressees specified by P&G. 
 6.2 Preservation Samples and
Retained Samples: OSGP shall take from each batch of the Products pursuant to this Agreement preservation samples/retained samples which OSGP shall retain for the shelf life of the particular batch and dosage forms of the Products plus one
year or longer as required by relevant regulations. For the avoidance of doubt, preservation samples/retained samples, as referred to herein, do not include samples retained for purposes of stability testing. OSGP shall take preservation samples of
raw materials and work-in-process materials as designated in writing by P&G. OSGP shall maintain these samples under cGMP conditions and review samples annually according to applicable regulations. 

6.3 Stability Testing: OSGP shall conduct stability-testing studies for the agreed Products, which include: all stability studies required
to support material changes (e.g. packaging, new suppliers, etc.); changes in the processes to produce items included in then-current stability program (i.e., those cases where only concurrent stability studies are needed, and/or which are initiated
after the decision to release batches involved in studies); and any new studies required as a result of manufacturing deviation(s) and any stability studies required as a result of manufacturing deviation(s). The results of this testing program
shall be available to P&G, without charge, upon request. 
 6.4 P&G Testing Rights: P&G shall have the right (but not
the obligation) to perform analytical testing on the Products manufactured by OSGP pursuant to this Agreement. 
 6.5 Quality
Disputes: Any claim by P&G that any of the Products at the time of delivery to P&G did not meet the Release Specifications or during their shelf life did not meet the Specifications must be made in writing to OSGP within thirty
(30) days after discovery by P&G of the problem. In the event that P&G claims that any of the Products failed to meet the Release Specifications or the Specifications and OSGP disagrees with P&G’s findings, OSGP shall test In
OSGP’s Norwich Plant testing facilities a retained sample from the same batch as the contested Product. P&G may, at its option and cost, have one of its personnel present for and actively participate in such testing. At P&G’s
discretion the testing may be done at a Third Party laboratory mutually agreed upon by the parties. The results of such Third Party testing shall be accepted by the two parties as final and binding. The cost of such analysis, and the cost of
testing, shipment, replacement or disposal of disputed Product, shall be borne by the party whose position is not substantiated by the testing. 

6.6 Customer Complaints: P&G shall, without delay, inform OSGP of any customer complaints of which it becomes aware which may relate to
the manufacturing or packaging of the Products. OSGP shall provide P&G, at OSGP’s expense, with all reasonable assistance in investigating complaints that are alleged to have arisen from manufacture or packaging of the Products hereunder.

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 8 of 19

 6.7 Health Authority Inquiries: OSGP shall be responsible for responding to any inquiry from
any legally competent health authority in the Territory regarding the Norwich Plant. For any such responses regarding or related to the Products, P&G shall review and approve the response prior to filing. OSGP shall without delay, at its own
expense, make available to P&G a copy of pertinent sections of any inspection report resulting from any inspection of the Norwich Plant by such health authority to the extent such report relates to the Products, the manufacture of the Products,
or Norwich Plant facilities used to manufacture the Products as well as a copy of any response(s) thereto. P&G shall provide OSGP with all reasonable assistance in responding to such inquiries and in handling inspections of the Norwich Plant for
the Products by such authorities. OSGP shall without delay inform P&G of any such inquiries and any requests for inspections of which it becomes aware. 
 6.8 Quality Assurance Key Elements OSGP agrees to comply with P&G Quality Standards as described in P&G’s Quality Assurance Key Elements (QAKE) Assessment and all future
revisions thereto. P&G shall use said QAKE Assessment periodically to audit OSGP’s Norwich Plant and shall provide OSGP a written report following said audit. For all Products that OSGP produces for P&G and all facilities and systems
supporting such production, should OSGP’s audit result in a score less than 100%, OSGP shall develop and implement, and P&G shall approve in writing, a detailed plan to improve OSGP’s systems. P&G will provide a copy of the QAKE
manual to OSGP, which shall be incorporated as appropriate into OSGP’s operating procedures used for production of Products covered by this Agreement. Should OSGP fail to meet the agreed-upon success criteria on a mutually acceptable time
schedule, or fall below a QAKE score of 100% P&G shall have the right to notify OSGP of OSGP’s failure to perform per Article 11. 
 In
the event that the parties agree on changes to quality assurance and manufacturing systems, and such changes require capital or increased staffing to implement, the parties shall negotiate in good faith to determine the extent to which each party
shall bear the costs of such changes. 
 7 SUPPLY OF PRODUCTS: 
 7.1 Approval & Disposition of Scrap: OSGP may not scrap or otherwise destroy any of P&G’s Products without P&G’s prior written authorization. In situations where
scrapping is authorized, OSGP agrees to provide to P&G written documentation assuring that the Products have been scrapped in a timely manner and by a means approved by P&G. In such approved scrapping situations the Materials cost of Product
scrapped and the physical disposition costs are for P&G’s account. The manufacturing expense cost of Product scrapped due to a problem Within OSGP Control is for OSGP’s account. 
 8 CHANGE MANAGEMENT 
 8.1 Non-Discretionary Changes: With respect to
changes to the Specifications and/or the Printed Matter which are required by applicable law, rule or regulation (including but not limited to changes required by the FDA or other legally competent authority) (collectively, “Non-Discretionary
Changes”), the parties shall co-operate in making such changes promptly and, unless otherwise agreed, the costs of making and/or implementing 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 9 of 19

 
such changes and the costs of the scrapping of Materials and Product necessitated by any such changes shall be the responsibility of P&G. Any such changes shall be evaluated using
P&G’s Change Control process for conformance to cGMP and other applicable health authority regulations. OSGP may not implement any Non-Discretionary Change without receiving written agreement in advance from P&G. 

8.2 Discretionary Changes: With respect to changes to the Specifications and/or the Printed Matter which are not required by applicable
law, rule or regulation (including but not limited to changes not initially proposed or required by the FDA or other legally competent authority) (collectively, “Discretionary Changes”), the parties shall, to the extent commercially
reasonable under the circumstances, cooperate in making such changes and the party initiating such change(s) shall bear the costs of making and/or implementing such changes and the costs of the scrapping of Materials (including but not limited to
raw and packaging Materials, work in process, inventory and labeling materials) necessitated by any such changes. Any such changes shall be evaluated using P&G’s Change Control process for conformance to cGMP and other applicable health
authority regulations. OSGP may not implement any Discretionary Change without receiving written agreement in advance from P&G. Costs associated with complying with applicable cGMP shall be the responsibility of OSGP. Cost reduction savings that
result from Discretionary Changes shall be shared to the extent that the total costs to develop and implement the changes are shared. 
 8.3
Disclaimer of Incidental Damages: Notwithstanding anything herein to the contrary, neither party shall be liable to the other for any consequential or special damages and/or lost profits resulting from a change to the Specifications
and/or to the printed matter as a result of any change thereto pursuant to this Article 10. 
 8.4 Authorizations: During the Term
of this Agreement OSGP shall obtain and maintain in force all licenses and authorizations necessary for OSGP to Contract Manufacture Product as contemplated herein. OSGP shall bear the full cost and expense of so obtaining and maintaining such
licenses and authorizations. P&G shall give OSGP all help reasonably necessary to assist OSOP in so obtaining and maintaining such licenses and authorizations and shall bear the full cost and expense of so assisting OSGP. 

9 [*****] 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 10 of 19

 10 INITIATIVES AND PROJECTS: P&G will communicate to OSGP product initiatives or projects
that P&G desires to conduct at OSGP’s Norwich Plant. Planning for implementation of such project activity will be included as part of production planning for P&G requirements at OSGP’s Norwich Plant. P&G may require the
participation of other outside contractors in initiatives or project work conducted at OSGP’s Norwich Plant. Access to the Norwich Plant and participation by such contractors will not be prohibited by OSGP subject to execution of appropriate
confidential disclosure agreement(s) and P&G providing OSGP reasonable notice of such contractor(s). 
 11 TERM 

11.1 Initial Term: The initial term of this Agreement, “Initial Term”, begins July 1, 2005 and ends June 30, 2008,
unless terminated earlier pursuant to terms contained in this Agreement. 
 11.2 Extension: P&G may, at its option, extend
this Agreement for any or all of the Contract Manufacturing Services, up to OSGP’s production capacity, under the terms and conditions of this Agreement for successive periods of one year each up to a maximum period of five (5) years by
notifying OSGP in writing of the extension within at least three hundred sixty (360) days prior to the expiration of the Initial Term or any extension thereof, (the Initial Term plus any such extensions, the “Term”). 

11.3 Termination: Upon termination of this Agreement OSGP shall cease all and any use of Intellectual Property acquired from P&G,
return to P&G or its designee without delay all Intellectual Property belonging to P&G, and shall refrain for five years thereafter from the manufacture of products which are the same as or directly competitive to P&G Products, for
themselves or for any Third Party without P&G’s prior written agreement. 
 12 PRICE: 

12.1 Charges And Prices: OSGP will charge P&G [*****] USD per kg for Contract Manufacturing Services performed at forecast production
volume for the term of the Agreement. 
 12.2 PRICE (S) shall be firm through June 30, 2006. SELLER may reduce PRICES at
any time. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 11 of 19

 SELLER has the right to increase any PRICE specified herein due to raw, packaging or
miscellaneous material costs on July 1st each year,
provided SELLER has given BUYER at least thirty (30) calendar days’ advance written notice of such change. 
 These revised PRICES
shall become effective on 30 calendar days after BUYER’s receipt of such notice (“PRICE CHANGE DATE”) unless BUYER provides SELLER with a written objection prior to the PRICE CHANGE DATE (“PRICE CHANGE OBJECTION”). If BUYER
provides a PRICE CHANGE OBJECTION prior to the PRICE CHANGE DATE, the PARTIES shall promptly discuss the reason for the PRICE CHANGE OBJECTION and attempt to resolve the same per Paragraph 14.3. If the PARTIES cannot resolve the PRICE CHANGE
OBJECTION within 30 calendar days, BUYER may (i) purchase the GOODS from any other supplier in which case the obligations, including, but not limited to, any purchase and sale requirements and/or commitments, if any, of BUYER and SELLER
hereunder shall be reduced accordingly; or (ii) terminate this AGREEMENT without any penalty, liability or further obligation. 
 12.3
Price Change Audit: Buyer shall have the right to initiate an audit to verify the adjustments to price and/or data pertaining to the adjustments as used by Seller in revising the price. The intent of the audit would be to insure that
market-based pricing adjustments are passed through to Buyer in the amounts actually incurred by Seller. The audit is not intended to verify absolute price or to force pass-through of non-market-based pricing adjustments. 

In order to initiate such an audit, Buyer shall provide written notice to Seller of its desire to audit price adjustments in accordance with the terms of
this Paragraph. Buyer shall initiate such audits not more frequently than once every twelve (12) months. In the event Buyer initiates such an audit, the firm of independent certified public accountants which is regularly retained by Seller to
audit its finances shall conduct such audit. 
 The auditing firm will maintain the confidentiality of the data reviewed and will either verify
the correctness of such price adjustment or advise the parties of the composite adjustment required to make a correction. If a correction is warranted, the price will thereafter be adjusted by the parties in accordance with such corrected data and
calculations, and any deficiency or overage in past payments for the goods sold and purchases under this Agreement resulting from such incorrect cost data or calculations shall be corrected by payment, within thirty (30) days, of the amount of
such deficiency or average. In all events, Buyer shall pay any and all costs associated in any way whatsoever with the audit procedure. 

12.4 Extra Charges: Any charges that OSGP proposes to charge P&G beyond those included in the prices agreed to in this Agreement, its
extensions, Supplemental Agreements or amendments, or related purchase orders, must be approved in writing by P&G prior to OSGP incurring or accepting such charges. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 12 of 19

 13 DELIVERY: 
 13.1 Delivery Terms: Delivery terms shall be Ex-works, the OSGP Norwich Plant. OSGP will be responsible for loading the carrier for shipment. OSGP shall ship Products on a carrier or
carriers specified by P&G in accordance with P&G’s purchase order form or as otherwise directed by P&G in writing. OSGP shall assist P&G in selecting appropriate carriers as requested. All such Products shipped hereunder shall
have at least twelve (12) months from their original expiration date remaining at the time of shipment to P&G customers unless mutually agreed to plans documented in appropriate SLEA’s for specific Product(s) or Unit(s) indicate a
different minimum number of months remaining until the expiration date at the time of shipment is acceptable. 
 13.2 Alternate
Shipping: OSGP may use alternate shipping methods to expedite delivery to P&G if both parties agree. In such cases, OSGP must receive P&G’s approval prior to the use of any carrier other than those on P&G’s approved
carrier list. Additional shipping costs resulting from expedited deliveries or use of alternate carriers will be at OSGP’s expense where the cause was Within OSGP Control or will be at P&G’s expense where required by P&G for
reasons not Within OSGP Control. 
 13.3 Refused Entry: In the event that the customs authorities of the destination country
refuse entry of any Products for reasons Within OSGP Control hereunder, except where appropriate for P&G’s failure to obtain the necessary import license or pay duty, P&G will not be responsible to pay for the same and, if payment has
already been made, OSGP will reimburse P&G in full. OSGP will be responsible for the repatriation of such Products at OSGP’S own cost. 

14. PAYMENT TERMS: Net thirty (30) days from receipt by P&G of a complete and correct invoice. 

15 INVOICING: OSGP shall include with each invoice required information as agreed and documented in the Service Level Execution Agreements
(SLEA’s). P&G may withhold payment of OSGP’S invoice until the provisions of this paragraph have been fulfilled. Payment to OSGP shall be in United States dollars. 
 16 COMPLIANCE WITH LAWS AND SAFETY MEASURES: OSGP represents and warrants that it is and will, and that the Products and Contract Manufacturing Services (including after being incorporated
into any finished products) are and will, at all times, be in full compliance with all applicable laws, regulations, rules, judgments, orders and decrees, including, without limitation, those related to intellectual property, customs, labor,
employment, working conditions, board of health, environmental matters, and Good Manufacturing Practices (GMP’s). OSGP also represents and warrants that it has obtained and will maintain all licenses, consents and permits required to perform
lawfully this Agreement. OSGP assumes sole responsibility for taking all necessary health and safety precautions for producing Products on behalf of P&G pursuant to this Agreement. These precautions include, without limitation, such things as
proper control of ventilation, the wearing of adequate protective clothing, installation, and proper utilization of appropriate environmental control equipment. OSGP will inform P&G of any regulatory agency inspection, such as an OSHA
inspection, which involves P&G Products or the Contract Manufacturing Services to produce these Products. OSGP is responsible for any audit follow-up or response. P&G Will provide OSGP information P&G possesses which is needed by OSGP to
respond to such audits. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 13 of 19

 17 ACCEPTANCE AND RETURN: Any Products manufactured by OSGP on behalf of P&G that do not
comply with the Specifications at any time during the shelf-life for such Products may, at P&G’s option, be (i) returned to OSGP at OSGP’s expense for credit to P&G at the full price as defined by the Unit pricing plus
expenses associated with such return, including, without limitation payment or reimbursement of customs duties and freight charges, (ii) scrapped by P&G, at OSGP’s expense, in which case P&G will be relieved of any payment
obligations with respect thereto or (iii) reworked by P&G or OSGP, at OSGP’s expense. P&G will also have the remedies set forth in subparts (ii) and (iii) above with respect to any of P&G’S finished Products
involving Contract Manufacturing Services performed by OSGP that do not comply with the representations and warranties set forth in this Agreement. Additionally, when numbers ii) or iii) above are applicable, the expenses for which OSGP will be
responsible include, without limitation, P&G’S cost of inspecting, recovering, and sorting the Products produced hereunder and P&G’S cost of obtaining replacement Products (including raw and packaging materials, scrapping Products
produced for P&G, and manufacturing additional Products on behalf of P&G). The rights and remedies set forth in this Agreement are not exclusive and nothing herein will be interpreted to limit in any manner the rights and remedies the
parties will have available to them pursuant to the relevant governing law. 
 18 ACCESS FOR P&G’S REPRESENTATIVES: OSGP
will permit P&G’s representatives access to any area of OSGP’s facilities and records having to do with the fulfillment of this Agreement upon reasonable notice by P&G. Should security requirements of other customers of OSGP create
conflict with this right, P&G shall be so informed and compatible scheduling arranged. 
 19 SECURITY PRECAUTIONS: OSGP agrees
to take appropriate security precautions requested by P&G including, but not limited to, prohibiting Third Parties from being present during production of P&G’s Products unless authorized in writing by P&G. P&G reserves the
right to reduce or discontinue its purchases under this Agreement, its extensions or related purchase orders, without further obligation, for violations of security practices agreed to by P&G and OSGP. 

20 CONFIDENTIALITY: Neither party will use (other than for the performance of this Agreement) or disclose to any Third Party any
Confidential Information. This obligation shall survive the expiration or termination of this Agreement. 
 21 INTELLECTUAL
PROPERTY. All right, title and interest in the Intellectual Property and other proprietary information to be used in connection with the Products are owned by P&GP and shall remain so at all times. P&GP has the right at all
reasonable times to inspect the services and goods sold or otherwise provided by OSGP using any of the Intellectual Property, as well as the facilities and methods of production and delivery of such goods and services. 

By acceptance of this Agreement and in consideration thereof, OSGP warrants and agrees that with respect to any article(s), chemical component(s) or
composition(s) 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 14 of 19

 
furnished by OSGP to any Third Party (excluding the Contract Manufacturing Services provided to or on behalf of P&G), OSGP will not use any P&G patents, copyrights, or similar
intellectual property rights without P&G’s prior written consent and will not infringe on any such P&G patents, copyrights or similar intellectual property rights. 
 If P&G is unknowingly benefiting from a Third Party’s patent, copyrights or similar intellectual property, OSGP will indemnify and save P&G harmless from and against claims by a Third Party
that P&G is infringing on such Third Party’s patents, copyrights or intellectual property with respect to products manufactured for a Third Party by OSGP. 
 P&G agrees to hold OSGP harmless with respect to liability for infringement, which OSGP may incur because of any allegations that the Products produced hereunder, the formula(e) or the specifications
of P&G violate or infringe any patents. OSGP agrees that P&G or P&G’s other suppliers (with respect to their activities on behalf of P&G) shall have immunity from suit by OSGP under any patents arising out of the performance of
this Agreement. 
 22 OSGP’S INDEMNIFICATION OF P&G: OSGP will indemnify, defend and hold P&G harmless from and
against all claims, losses, damages, costs and expenses (including without limitation reasonable fees and expenses of attorneys incurred in investigation or defense of any third-party claim or action, (collectively “Damages”) arising out
of or related to (i) OSGP’S breach of any representation, warranty, covenant or other obligation pursuant to this Agreement, including, without limitation, the failure of any Contract Manufacturing Services to be in compliance with the
Specifications where such failure was Within OSGP Control, (ii) any manufacturing defect of Products produced hereunder, or (iii) the negligence, gross negligence, bad faith or willful misconduct of OSGP, its employees or other
representatives. OSGP agrees to provide at least $5,000,000 of commercial liability insurance in support of this indemnity with companies reasonably acceptable to P&G, which insurance will carry an endorsement naming P&G and its affiliates
as co-insured. 
 23 CHANGE IN OSGP’S OWNERSHIP: If for any reason OSGP decides to sell or transfer voluntarily any or all
the Norwich Plant facilities used in the fulfillment of this Agreement to any Third Party, OSGP will provide P&G with at least six (6) months or with as much notice as legally possible prior written notice of its intent to transfer or sell
such operation. P&G reserves the right to reduce or discontinue purchases under this Agreement, or terminate this Agreement, without obligation, if any new entity or person obtains whole or greater than 50% corporate ownership of OSGP without
P&G’s consent. Such an agreement not to be unreasonably withheld by P&G. 
 24 TERMINATION FOR CAUSE: In the event
(i) a party (the “Defaulting Party”) breaches any representation, warranty, covenant or other obligation of this Agreement, or ii) the Defaulting Party becomes unable to pay its bills as they become due in the ordinary course, a
trustee or receiver of such party’s property is appointed, the Defaulting Party makes an assignment for the benefit of creditors, a petition in bankruptcy is filed by or against the Defaulting Party or the Defaulting Party terminates or
liquidates its business, the other party (the “Non-Defaulting Party”) will have the option to terminate this 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 15 of 19

 
Agreement, without further obligation, immediately upon notice of such termination to the Defaulting Party. If the Defaulting Party is OSGP, then OSGP will make available for P&G’s
removal any finished Products, Materials, or other of P&G’S property then under OSGP’s control. OSGP further agrees not to encumber such Products or Materials in any way. Termination or expiration of this Agreement will not relieve
either party of any liability it may have to the other arising out of or related to acts or omissions prior to such termination or expiration. 

25 CONTINUATION OF SUPPLY: If either party terminates this Agreement pursuant to either paragraph 23 or 24 hereof, then the parties’
obligations with respect to manufacturing and supply of PRODUCTS hereunder shall continue, unless earlier terminated by P&G, for a period of eighteen (18) months from the initial termination date, or until P&G can obtain commercial
supply from another source, whichever is earlier at which point OSGP shall have no further obligation to continue to Manufacture the PRODUCTS. In addition, OSGP agrees to use best efforts to transition the manufacturing process to a
P&G-designated third party prior to cessation of supply by OSGP. For the avoidance of doubt the costs for any transfer of PRODUCTS shall be borne solely by P&G, unless specified otherwise in this Agreement. 

26 ASSIGNMENT: Not withstanding the provisions of Article 25 neither OSGP nor P&G may assign its rights or delegate or subcontract this
Agreement or its obligations pursuant hereto to any Third Party without the prior written consent of the other; provided, however, P&G may so assign or delegate to any of its Affiliates without OSGP’S prior consent, and provided that if all
or substantially all of the assets of P&G are sold to a Third Party, P&G may assign its rights and obligations under this Agreement to such Third Party. 
 27 CONTRACTOR STATUS: OSGP is an independent contractor and nothing herein contained and no course of dealing between the parties will create or be deemed to create an agency, partnership,
joint venture or any other relationship, fiduciary or otherwise between the parties hereto. OSGP assumes sole responsibility for the direction and control of its employees involved in performing Contract Manufacturing Services and such employees
shall for all purposes remain employees of OSGP. Except as otherwise expressly indicated herein, OSGP is not granted any right or authority to assume or to create an obligation or responsibility, express or implied, on behalf of or in the name of
P&G or bind P&G in any manner whatsoever. 
 28 REPORTING REQUIREMENTS: OSGP agrees to provide to P&G information and
reports, in a format and on a frequency requested by P&G and agreed to by OSGP. Costs for such services will be included in OSGP’s price as referenced in Article 14.2. P&G shall have the right to withhold payment if OSGP fails to
provide information or reports as mutually agreed. P&G reserves the right to reduce or discontinue its purchases under this Agreement, its extensions or related purchase orders, if OSGP fails to meet information or reporting requirements on a
recurring basis. 
 29 FORCE MAJEURE: 
 29.1 Force Majeure: P&G or OSGP shall not be deemed to be in breach hereof on account of any delay in delivery or other performance caused in whole or in part by, or

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 16 of 19

 
otherwise materially related to, the occurrence of any contingency beyond P&G’s or OSGP’s control, including but not limited to: war or hostility; failure or delay on land, water or
air transportation; act of any government or agency, subdivision or branch thereof; judicial action; strikes or other labor disputes; accident, fire, explosion, flood, epidemic, storm or other acts of God; shortage of fuel or power, delay or failure
to perform by any supplier; or, in general, any other contingency whatsoever (whether similar or dissimilar to those set forth herein) where P&G or OSGP has exercised ordinary care in the prevention thereof. 

29.2 Effects of Force Majeure: In the event of any contingency as described hereunder, P&G or OSGP shall give immediate notice thereof
to the other party. P&G or OSGP shall render the delayed performance in the manner as practicable as possible after such event of force majeure has ceased or otherwise abated sufficiently in order to permit it to do so without incurring any
material additional expense that it would not have had in the absence of such event of force majeure. 
 30 GOVERNING LAW AND
LANGUAGE: This Agreement shall be governed by and interpreted for any and all purposes in accordance with the laws of Ohio and Ohio Courts shall have jurisdiction of any disputes hereunder. The parties agree that the United Nations
Convention on International Sale of Goods will have no force or effect on transactions relating to this Agreement. The parties understand the English language and are fully aware of all terms and conditions contained herein. If any translation of
this Agreement is made into any language other than English, the English language version will continue to govern. 
 31 HEADINGS AND
REFERENCES: All section headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 
 32 AGREEMENT PRECEDENCE: Supplemental and/or transitional services agreements may be executed as appropriate, including but not limited to information technology, supply of P&G’s
external customers, other joint support by the parties, product stability testing, other quality assurance support, product development activity, and facilities maintenance. In the event of any conflict between this Agreement and any purchase order
form, service level execution agreements or other agreements which may be entered into by the parties and/or their affiliates governing the same matters sat forth herein, this Agreement will take precedence and its terms shall govern, unless such
subsequent agreement specifically refers to this Agreement and indicates that such subsequent agreement will take precedence over this Agreement. 
 33 MUTUAL SUPPORT: During the Term of this Agreement one party may desire the support of resources of the other party to conduct work not expressly covered by this Agreement but needed to
further the aims of both parties under this Agreement. Both parties desire to cooperate in a reasonable manner to the extent possible to provide requested support at a reasonable cost. Such requests for support shall normally be made at least 30
days in advance of the date needed. The party providing the requested support shall invoice the other party for any agreed charges and expenses on a no less than weekly basis. Such invoices shall be paid within 10 days. Neither party nor their

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 17 of 19

 
Affiliates have liability under this Agreement due to damage or loss of any type suffered as a result of performance or non-performance of the support requested and provided by one party to the
other. Details of support resource request agreements shall be documented in letters of agreement. 
 34 NOTICES: All notices
required or permitted pursuant to this Agreement will be in writing and will be deemed to be properly given when actually received by the person entitled to receive the notice at the address stated below, or at such other address as a party may
provide by notice to the other: 
  

					
	P&G:	  		  	
			
	 Mailing
	  		  	 Delivery

			
	 Procter & Gamble Pharmaceuticals, SARL
 47 Route de Saint-Georges
 1213 Petit-Lancy 1, Switzerland

Attention: Alasdair McGregor
	  		  	 Procter & Gamble Pharmaceuticals, SARL
 47 Route de Saint-Georges
 1213 Petit-Lancy 1, Switzerland

Attention: Alasdair McGregor

			
	OSGP:	  		  	
			
	 Mailing:
	  		  	
			
	 Outsourcing Services Group
 50 Tice Boulevard
 Woodcliff Lake, NJ 07677

Attention: Perry M. Morgan
	  	and	  	 OSG Norwich Pharm. Inc.
 6826 State Highway 12
 Norwich, NY 13815

Attention: Chris Calhoun, President

			
	 Paul, Hastings, Janofsky & Walker LLP

695 Town Center Drive, 17th Floor
 Costa Mesa, CA 92626
 Attention: Peter Tennyson, Esq.
	  		  	

 P&G and OSGP have caused their respective duly authorized representatives to execute this Agreement, acting as
agent(s) as set forth herein. 
  

									
	For:	 	Procter & Gamble Pharmaceuticals, SARL	 		 	For:	 	OSG Norwich Pharmaceuticals, Inc.
		 	 (P&G)
	 		 		 	 (OSGP)

					
	By	 	 /s/ Alasdair D McGregor
	 		 	By	 	 /s/ Christopher R. Calhoun

		 	 (Signature)
	 		 		 	 (Signature)

			
	 Alasdair D McGregor
	 		 	 Christopher R. Calhoun

	 (Name Typed)
	 		 	 (Name Typed)

					
	As:	 	 Purchasing Group Manager
	 		 	As:	 	 President

		 	 (Title)
	 		 		 	 (Title)

					
	Date	 	 30/1/2006
	 		 	Date	 	January 24, 2006

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 18 of 19

 SCHEDULES: 
 A. Example Certificate Of Analysis (COA) 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 19 of 19

 Schedule B — Example Certificate Of Analysis 

 

 

 GMP Statement/Batch Certificate 

 

			
	Product:	  	Calcium Carbonate 1250mg Tablets, Coated, BULK
		
	Manufacturing Date:	  	
	Retest Date:	  	
	 Calcium Starch Granulation
 Batch Number:
	  	
	Material Number:	  	
	 Core Tablets

Batch Number:
	  	
	Material Number:	  	
	Making Instruction & Version Number:	  	
	Special Event	  	 ̈No      ̈Yes   (attach documentation)
	Rework1 or
Reprocessing2:	  	 ̈No      ̈Yes   (attach documentation)
		
	 Coated Tablets

Batch Number:
	  	
	Material Number:	  	
	Making Instruction & Version Number:	  	
	Average Gross Weight:	  	
	Quantity:	  	
	Special Event	  	 ̈No      ̈Yes   (attach documentation)
	Rework or Reprocessing:	  	 ̈No      ̈Yes   (attach
documentation)

					
			
	Attachments (Testing):	  	 ̈	  	 Certificate of Analysis

			
	Retest data, Laboratory or Out-of-	  		  	
	Specification Investigations:	  	 ̈No      ̈Yes   (attach
documentation)

	
	
	 Additional Notes / Attachments:

	  

	  

	  

	  

 

	1	 Reworking – Subjecting an in-process drug, bulk process intermediate or final product of a single batch/lot an alternate manufacturing process due
to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre-approved as part of the marketing authorization. 

	2	 Reprocessing – Subjecting all or part of a batch or lot of an in-process drug, bulk process intermediate or bulk drug of a single batch/lot to a
previous step in the validated manufacturing process due to failure to meet predetermined specifications. Reprocessing procedures are foreseen as occasionally necessary and are validated and pre-approved by the quality control department or is part
of the marketing authorization. 

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 1 of 2

 Hereby we certify according to Commission Directive 2001/83/EEC, Art. 51, that this batch has been produced
and tested in accordance with the European Guide to Good Manufacturing Practises for Medicinal Products, Commission Directive 2003/94/EEC, or comparable accepted Good Manufacturing Practises guidelines (PIC, WHO). 

The product was stored under the approved storage conditions. Intermediate material was used within its approved retest period unless otherwise noted
above. 
  

					
	  
	 		 	  

	OSG Quality Assurance	 		 	Date

  
 Calcium Contract for
Europe PFI 11-9-0512 
 Rev. 1/24/06 

  
 Page 2 of 2Letter Agreement

 Exhibit 10.59 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 
 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2.

 [*****] INDICATES OMITTED MATERIAL THAT IS THE 
 SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST 
 FILED SEPARATELY WITH THE COMMISSION. 

THE OMITTED MATERIAL HAS BEEN FILED 
 SEPARATELY
WITH THE COMMISSION. 
 RESTRICTED 
 Procter & Gamble Pharmaceuticals, S.A.R.L 
 Route de
Saint Georges 47 
 1213 Petit-Lancy 1 

Geneva, Switzerland 
 September 11, 2006 
 OSG Norwich Pharmaceuticals, Inc. 

Attention: Christopher R. Calhoun, President 

6826 State Highway 12 
 Norwich, NY 13815

  

	Subject:	Amendment to the Contract Manufacturing Services Agreement between Procter & Gamble Pharmaceuticals, S.A.R.L. (“P&G”) and OSG Norwich
Pharmaceuticals, Inc. (“OSGP”), executed on 30 January 2006. 

 Dear Mr. Calhoun: 

This letter will serve to amend the above referenced Agreement. Capitalized terms not otherwise defined herein shall have the meanings set forth in the
Agreement. Except as amended hereby, the Agreement shall remain unchanged and in full force and effect. 
 The Contract Manufacturing Services
Agreement (“CMSA”) and subsequent amendments shall be amended as follows: 
 1. Replace Sections 11.1, 12.1, 12.2, and 34 in their
entirety with the applicable Sections below: 
 11.1 TERM: The term of this Agreement (“Term”) begins July 1, 2005 and
ends June 30, 2011, unless terminated earlier pursuant to the terms contained in this Agreement. 
 12.1 CHARGES AND PRICES: The
prices for the Products, including taxes, shall be as set forth in Schedule C-1. SGP will charge P&G for Contract Manufacturing Services performed under this Agreement. 

 

	12.2	PRICE(S): 

 12.2.1
PRICING: Prices for service charge on Balchem are firm through June 30, 2008. Thereafter, OSGP may request a price change annually as of July 1st of each year, based upon the [*****] for the preceding Calendar Year for all toll
or manufacturing costs. If the [*****] reflects a price increase, then OSGP may request an increase, not to exceed [*****]. Cost changes for Balchem associated with materials, without limitation by the [*****] will be passed through to P&G as
set forth in Schedule C-3. Costs for service charge and materials in the “New Calcium” will be updated when the specifications, formula, process, and unit operations are finalized with no time limitation as to when this occurs. 

 

	 	12.2.2	CALCIUM PRICE TIER RECONCILIATION: Prior to the beginning of each P&G’s fiscal year the price applicable for such year shall be agreed upon by the
Parties based on P&G’s non-binding, rolling twelve (12) month forecast of P&G’s demand for Calcium Product (“Forecasted Volume”). At the end of each Calendar Year, but no later than by the end of the first month of
the next Calendar Year, the Parties shall agree on the units of Calcium Product actually released for shipment to P&G (“Purchased Volume”) and the price paid by P&G for units of Calcium Product released for shipment during such
year shall be reconciled as follows: (i) if the price for the Forecasted Volume is greater than the price paid by P&G for the Purchased Volume, OSGP shall reimburse P&G the amount equal to the difference in price between the Forecasted
Volume and the Purchased Volume times the Calcium Product released for shipment; or (ii) if the price for the Forecasted Volume is lower than the price paid by P&G for the Purchase Volume, P&G shall reimburse OSGP the amount equal to
the difference in price between the Forecasted Volume and the Purchased Volume times the Calcium Product released for shipment. 

  

	
	RESTRICTED
	1st Amendment to P&GP OSGP-SARL CSMA dated 9-11-2006 .doc
	  
 Page 1 of 4

 RESTRICTED 

 

 34 NOTICES: All notices required or permitted pursuant to this Agreement will be in writing
and will be deemed to be properly given when actually received by the person entitled to receive the notice at the address stated below, or at such other address as a party may provide by notice to the other: 

P&G: 

					
	 Mailing
	 	 	 	 Delivery

	 Procter & Gamble Pharmaceuticals, SARL
 47 Route de Saint-Georges
 1213 Petit-Lancy 1, Switzerland

Attention: Tania Zwicky
	 		 	 Procter & Gamble Pharmaceuticals, SARL
 47 Route de Saint-Georges
 1213 Petit-Lancy 1, Switzerland

Attention: Tania Zwicky

			
	OSGP:	 		 	
			
	 Mailing:
 Outsourcing Services Group
 50 Tice Boulevard
	 	  
 and
	 	 OSG Norwich Pharmaceuticals. Inc.
 6826 State Highway 12

	 Woodcliff Lake, NJ             07677

Attention: CFO
	 		 	 Norwich, NY 13815

Attention: Christopher R. Calhoun, President

 III. Add Sections 38, 39, 40, 41, and 42 as provided below: 
 38 GENERAL INSURANCE POLICY
REQUIREMENTS: OSGP shall maintain and cause its subcontractors to maintain at their own expense the insurance coverage set forth in Section 38.1, entitled Insurance Coverage, in full force and effect during the Term of this Agreement with
underwriters acceptable to P&G and having an A. M. Best’s rating of “A VIII” or better or its equivalent rating where not available. OSGP shall provide P&G with a copy of the Certificate(s) of Insurance. All insurance policies
shall provide for a thirty (30) calendar days prior written notice to P&G in the event of termination, cancellation, non-renewal, or a material change to the requirements as set forth in this Article 38. All insurance policies shall be
primary without right of contribution from any of P&G’s insurance carriers. 
 38.1 INSURANCE COVERAGE 

38.1.1 Commercial General Liability including Products Completed Operations and Blanket Contractual “occurrence form” coverage with the
following limits of liability: (i) $5,000,000 per occurrence combined single limit for Bodlly Injury and Property Damages; and (ii) minimum $5,000,000 limit of liability per occurrence for Products-Completed Operations, Product Liability
and Contractual Liability to include liability assumed under this Agreement. 
 38.1.2 Workers Compensation will provide no-fault
statutory benefits, as prescribed by the law of the state or countries in which the work is performed, to OSGP’s employees due to a job-related injury resulting from an accident or occupational disease. Employers’ Liability is to be
provided in the minimum amount of $1,000,000 per occurrence for all sums that the insured becomes legally obligated to pay as damages because of bodily injury by accident or disease sustained by the insured arising out of and in the course of
employment. 
 38.2 ADDITIONAL INSURED: The Commercial General Liability policy shall include P&G as Indemnitee (the
“Indemnitee”) as additional insured in connection with the activities contemplated by the scope of this Agreement to be stated explicitly on the Certificate(s) of Insurance. 
 38.3 WAIVER OF SUBROGATION: OSGP hereby irrevocably and unconditionally waives and shall cause its insurers to irrevocably and unconditionally waive any rights of subrogation for claims against the
Indemnitee to be documented to P&G’s satisfaction. 
 38.4 LIABILITY OF OSGP: OSGP’s compliance with this Section shall not
relieve OSGP of any liability to the Indemnitee arising under any other provision of this Agreement except to the extent that such monies recovered are paid to the Indemnitee to reduce OSGP’s obligations to the Indemnitee. OSGP shall be liable
for any and all deductibles it may incur in connection with any of the policies listed in this Article 38. 

  

	
	RESTRICTED
	1st Amendment to P&GP OSGP-SARL CSMA dated 9-11-2006 .doc
	  
 Page 2 of 4

 RESTRICTED 

 

 39 EXPERIMENTAL ORDERS (“EO”, “EO’s”): P&G may from time to time
require OSGP support to conduct EO’s in order to perform operations, test, develop new materials, processes, formulations or products, or to conduct similar development activities. OSGP will meet all reasonable requests to provide this support.

 39.1 SCHEDULING: OSGP will meet P&G requests for EO support provided that the forecasts for such support are received by OSGP not
later than thirty (30) days prior to the time the EO must begin as determined by P&G. This requirement notwithstanding, P&G will use its best efforts to provide a ninety (90) day forecast for all EO requirements. Furthermore,
P&G must provide the relevant protocols, Standard Operating Procedures (SOPs), and other requirements necessary for the proper execution of the EO to OSGP no later than seven (7) business days prior to the scheduled start date of each EO.
Notwithstanding the foregoing, if P&G is unable to meet these scheduling forecast requirements for an EO, OSGP will use its best efforts to provide the resources necessary to conduct the EO. 

39.2 MATERIALS HANDLING: Unless agreed to otherwise by the parties, the procedures and responsibilities for the ordering, receiving, testing,
handling, storage, removal and disposal of all raw and packaging materials for an EO will be in accordance with the same procedures and responsibilities for the ordering, receiving, testing, handling, storage, dispensing, release, removal and
disposal of all raw and packaging materials for Products in this Agreement. 
 39.3 SECURITY: OSGP will take all reasonable and necessary
precautions within its control to ensure that third parties other than P&G and OSGP cannot observe or otherwise determine P&G’s activities or intentions with regard to the EOs. Such precautions may include but are not limited to
preventing such third parties from observing schedules, raw and packaging materials, specifications, logbooks, batch records, finished product, shipments, procedures, instructions or other similar activities, postings or materials that would allow
such third parties to determine the nature, or intended outcomes of such EOs. 
 39.4 COST PROPOSAL: Within ten (10) business days
of OSGP’s receipt of a forecast from P&G for an EO and sufficient information from P&G to determine OSGP’s costs for conducting the EO, OSGP shall provide P&G with a cost proposal and plan for conducting such EO. [*****]

 39.5 INVOICE: OSGP will invoice P&G for each EO upon completion and distribution of the final reports associated with that EO.
Payment terms for EO’s will be 30 days from P&G’s receipt of a properly completed invoice. 
 40 [*****] 

41 OSGP DIVERSITY PROGRAM: If OSGP has operations (production, sales, administrative) physically located in the United States of America which are
involved in OSGP’s performance under this Agreement, then OSGP is expected to develop procurement and contracting strategies aimed at meeting the goals of P&G’s minority business development program (a.k.a. Supplier Diversity Program).
Such strategies shall include sourcing methods, goals, reporting and efforts to encourage sub-contractors’ use of minority vendors. OSGP shall use its best commercial efforts that the use of such minority vendors shall reach or exceed 10% of
the price. OSGP shall report to P&G the amount of such minority vendor spending quarterly. 
 42 BUSINESS CONTINGENCY PLAN: Within
sixty (60) calendar days of P&G’s request, OSGP shall develop, draft and then submit to P&G for P&G’s approval a “business contingency plan” detailing supply assurance plans in

  

	
	RESTRICTED
	1st Amendment to P&GP OSGP-SARL CSMA dated 9-11-2006 .doc
	  
 Page 3 of 4

 RESTRICTED 

 

 
the event that a force majeure were to occur during the Term of this Agreement. P&G also maintains the right to award up to 30% of its Calcium Product requirements to an alternate source in
part to maintain sufficient supply assurance to meet its needs in the event of force majeure. 
  

									
	Accepted and Agreed to:	 		 		 	
			
	OSG Norwich Pharmaceuticals, Inc.	 		 	Procter & Gamble Pharmaceuticals, S.A.R.L.
					
	By:	 	 /s/ Christopher R. Calhoun
	 		 	By:	 	 /s/ Alasdair D McGregor

					
	Name:	 	Christopher R. Calhoun	 		 	Name:	 	Alasdair D McGregor
	Title:	 	President	 		 	As:	 	Associate Director, ESO Purchases
		 	OSG Norwich Pharmaceuticals, Inc.	 		 		 	Procter & Gamble, Pharmaceuticals S.A.R.L.
					
	Date:	 	 10 November 2006
	 		 	Date:	 	 14th November 2006

  

	
	RESTRICTED
	1st Amendment to P&GP OSGP-SARL CSMA dated 9-11-2006 .doc
	  
 Page 4 of 4

 Schedule C-1 
  

			
	Years 06/07 and 07/08 Line Item Pricing	  	7/10/06

  

											
	 Material No.
	  	 Description
	  	 UOM
	  	 Campaign 
Assumptions
	 	  	 06/07 and
 07/08 Item

Pricing

	 Manufacturing only, no packaging step
	  		  				  	
					
	15121219	  	Calcium Carb Tabs (Belchem)	  	Kg	  	 	25 lots	  	  	Schedule C-2
	TBD	  	Calcium Carb Tabs (New Formula w/C)	  	Kg	  	 	25 lots	  	  	Schedule C-2
	TBD	  	Calcium Carb Tabs (New Formula w/D)	  	Kg	  	 	25 lots	  	  	Schedule C-2

											
	OSG Norwich	 	7/10/2006	  		  		  		  	

 Restricted and Highly Confidential 
 Full Pricing w/ “All” included – (per kg pricing) 
  

																													
	 MM tabs/year
	 	  	Kgs/Year @ ave AGW	 	  	Balchem
SARLw/
[*****]	 	  	New
Calcium
w/o D
SARL	 	  	New
Calcium
w/ D
SARL	 	  	 Pricing Includes

				  				  				  				  	 	Yes	  	  	 	Yes	  	  	 	Yes	  	  	Mfg Costs
				  				  				  				  	 	No	  	  	 	No	  	  	 	No	  	  	Finished Product Testing
				  				  				  				  	 	Yes	  	  	 	Yes	  	  	 	Yes	  	  	Raw Mats
				  				  				  				  	 	Yes	  	  	 	Yes	  	  	 	Yes	  	  	QS Items
				  				  				  				  	 	Yes	  	  	 	Yes	  	  	 	Yes	  	  	SARL Shipping Materials
				  				  				  				  	 	Yes	  	  	 	Yes	  	  	 	Yes	  	  	W&S
	
	 	NON-SCALE UP PRICING
	 	0	  	  	 	99	  	  	 	0	  	  	 	141,372	  	  	$	[*****]	  	  	$	[*****]	  	  	$	[*****]	  	  	
	 	100	  	  	 	200	  	  	 	142,800	  	  	 	285,600	  	  	$	[*****]	  	  	$	[*****]	  	  	$	[*****]	  	  	
	 	200	  	  	 	300	  	  	 	285,600	  	  	 	428,400	  	  	$	[*****]	  	  	$	[*****]	  	  	$	[*****]	  	  	
	 	300	  	  	 	400	  	  	 	428,400	  	  	 	571,200	  	  	$	[*****]	  	  	$	[*****]	  	  	$	[*****]	  	  	
	 	400	  	  	 	& up	  	  	 	571,200	  	  	 	& up	  	  	$	[*****]	  	  	$	[*****]	  	  	$	[*****]	  	  	
	
	 	SCALE UP PRICING (NPI FUNDED CAPITAL)
	 	0	  	  	 	99	  	  	 	0	  	  	 	141,372	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	100	  	  	 	200	  	  	 	142,800	  	  	 	285,600	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	200	  	  	 	300	  	  	 	285,600	  	  	 	428,400	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	300	  	  	 	400	  	  	 	428,400	  	  	 	571,200	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	400	  	  	 	& up	  	  	 	571,200	  	  	 	& up	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	
	 	SCALE UP PRICING WITH [*****] ON SERVICE REVENUE (PGP FUNDED CAPITAL)
	 	0	  	  	 	99	  	  	 	0	  	  	 	141,372	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	100	  	  	 	200	  	  	 	142,800	  	  	 	285,600	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	200	  	  	 	300	  	  	 	285,600	  	  	 	428,400	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	300	  	  	 	400	  	  	 	428,400	  	  	 	571,200	  	  				  	$	[*****]	  	  	$	[*****]	  	  	
	 	400	  	  	 	& up	  	  	 	571,200	  	  	 	& up	  	  				  	$	[*****]	  	  	$	[*****]	  	  	

			
	 Schedule C-3
	 	Restricted and Highly Confidential

 Material Cost
Breakdown for SARL Calcium 
 7/14/2006 

 

 New Calcium 

 

									
	 Description
	  	Approximate %
of total
cost	 	  	Material Cost	 
			
	 Calcium granulation
	  	 	[*****]%	  	  	$	[*****] / kg	  
			
	 Opadry Coating (1)
	  	 	[*****]%	  	  	$	[*****] / kg	  
			
	 Miscellaneous materials
	  	 	[*****]%	  	  	$	[*****] / kg	  

 Balchem Calcium 

 

									
	 Description
	  	Approximate
% of total cost	 	  	Material Cost	 
			
	 Calcium granulation
	  	 	[*****]%	  	  	$	[*****] / kg	  
			
	 Opadry Coating (1)
	  	 	[*****]%	  	  	$	[*****] / kg	  
			
	 Miscellaneous materials (includes Opadry)
	  	 	[*****]%	  	  	$	[*****] / kg

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]